Personalized genomes and cardiovascular disease

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 1, 2015, Pages

  Musunuru, Kiran ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Harvard University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; TRIACYLGLYCEROL; WARFARIN; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ARTICLE; BASE PAIRING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DNA SEQUENCE; EXOME; FRAMINGHAM RISK SCORE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC RISK; GENOMICS; GENOTYPE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN GENOME; HUMAN GENOME PROJECT; INTERNATIONAL NORMALIZED RATIO; NEXT GENERATION SEQUENCING; PERSONALIZED GENOME; PHARMACOGENOMICS; PHENOTYPE; PREDICTION; PRIMARY PREVENTION; PROTHROMBIN TIME; REPRODUCTIVE FITNESS; SECONDARY PREVENTION; THROMBOEMBOLISM; TRIACYLGLYCEROL BLOOD LEVEL; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; GENETICS; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROCEDURES; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; TICLOPIDINE;

EID: 84923799089     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a014068     Document Type: Article

References (37)

1. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, et al. 2007. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116: 2563-2570.
2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. 2007. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 49: 1505-1516.
3. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. 2011. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: Systematic review and meta-analysis. BMJ 343: d4588.
4. Brautbar A, Ballantyne CM, Lawson K, Nambi V, Chambless L, Folsom AR, Willerson JT, Boerwinkle E. 2009. Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study. Circ Cardiovasc Genet 2: 279-285.
5. Caraco Y, Blotnick S, Muszkat M. 2008. CYP2C9 genotype- guided warfarin prescribing enhances the efficacy and safety of anticoagulation: A prospective randomized controlled study. Clin Pharmacol Ther 83: 460-470.
6. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, et al. 2009. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 373: 309-317.
7. Coronary Artery Disease (C4D) Genetics Consortium. 2011. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet 43: 339-344.
8. Eckman MH, Rosand J, Greenberg SM, Gage BF. 2009. Cost- effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 150: 73-83.
9. Epstein RS, Moyer TP, Aubert RE, O Kane DJ, Xia F, Verbrugge RR, Gage BF, Teagarden JR. 2010. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 55: 2804-2812.
10. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, et al. 2008. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84: 326-331.
11. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. 2003. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107: 2908-2913.
12. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, Jonasdottir A, Sigurdsson A, Baker A, Palsson A, et al. 2007. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316: 1491-1493.
13. Helgadottir A, Thorleifsson G, Magnusson KP, Grétarsdottir S, Steinthorsdottir V, Manolescu A, Jones GT, Rinkel GJ, Blankensteijn JD, Ronkainen A, et al. 2008. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 40: 217-224.
14. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. 2011. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: A systematic review and meta-analysis. JAMA 306: 2704-2714.
15. Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, Huang ZH, He Y, Chen KM, Xiang DK, et al. 2009. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: A prospective study in Chinese patients. Pharmacogenet Genom 19: 226-234.
16. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P. 2006. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108: 2244-2247.
17. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, et al. 2009. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360: 753-764.
18. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, Hirschhorn JN, Berglund G, Hedblad B, Groop L, et al. 2008. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358: 1240-1249.
19. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, et al. 2013. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 369: 2283-2293.
20. Lloyd-Jones DM, Nam BH, D’Agostino RB Sr, Levy D, Murabito JM, Wang TJ, Wilson PW, O’Donnell CJ. 2004. Parental cardiovascular disease as a risk factor for cardio- vascular disease in middle-aged adults: A prospective study of parents and offspring. JAMA 291: 2204-2211.
21. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, et al. 2007. A common allele on chromosome 9 associated with coronary heart disease. Science 316: 1488-1491.
22. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, et al. 2009. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360: 354-362.
23. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, et al. 2010. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. JAMA 304: 1821-1830.
24. Myocardial Infarction Genetics Consortium, Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM, Anand S, Engert JC, Samani NJ, et al. 2009. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 41: 334-341.
25. Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW. 2010. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 363: 1704-1714.
26. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlström B, Stafberg C, et al. 2013. A randomized trial of genotype- guided dosing of warfarin. N Engl J Med 369: 2294-2303.
27. Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, Guiducci C, Perola M, Jula A, Sinisalo J, et al. 2010. A multilocus genetic risk score for coronary heart disease: Case-control and prospective cohort analyses. Lancet 376: 1393-1400.
28. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, et al. 2007. Genomewide association analysis of coronary artery disease. N Engl J Med 357: 443-453.
29. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, et al. 2011. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 43: 333-338.
30. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. 2008. SLCO1B1 variants and statin-induced myopathy-A genomewide study. N Engl J Med 359: 789-799.
31. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L, French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. 2009. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360: 363-375.
32. Talmud PJ, Cooper JA, Palmen J, Lovering R, Drenos F, Hingorani AD, Humphries SE. 2008. Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men. Clin Chem 54: 467-474.
33. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, et al. 2010. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466: 707-713.
34. Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le Cessie S, Maltezos E, van der Meer FJ, et al. 2013. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 369: 2304-2312.
35. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS. 2009. The SLCO1B1 5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54: 1609-1616.
36. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P. 2007. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121: 23-34.
37. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, et al. 2010. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial. Lancet 376: 1320-1328.